

10668 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Table 1.--Antiemetics
[Survey Period - February 1972-June 1972]

Manufacturer	Declared potency (mg.)	Number batches sampled and analyzed	Number defective samples
<u>Cyclizine HCl Tablets:</u>			
Burroughs Wellcome Co.	50.0	$\frac{6}{6}$	$\frac{0}{0}$
Total			
<u>Dimenhydrinate Tablets:</u>			
Cord Laboratories, Inc.	50.0	2	0
Paul B. Elder Co.	50.0	2	0
The Lannett Co., Inc.	50.0	1	0
Linden Labs., Inc.	50.0	1	0
Phoenix Labs., Inc.	50.0	1	0
Richlyn Laboratories.....	50.0	1	0
G. D. Searle & Co.	50.0	6	0
West-Ward, Inc.	50.0	$\frac{1}{15}$	$\frac{0}{0}$
Total			
<u>Meclizine HCl Tablets:</u>			
Pfizer, Inc.	25.0	$\frac{4}{4}$	$\frac{0}{0}$
Total			
<u>Trimethobenzamide HCl Capsules:</u>			
Hoffman-La Roche Inc.	100.0	1	0
Total	250.0	$\frac{4}{5}$	$\frac{0}{0}$
<u>Trimethobenzamide HCl Injection:</u>			
Hoffman-La Roche Inc.	100.0 mg/cc	$\frac{3}{3}$	$\frac{0}{0}$
Total			